Stock RGLS REGULUS THERAPEUTICS INC.
Add to a list
To use this feature you must be a member
Log inSign up

Other languages Regulus Therapeutics Inc.

Equities

RGLS

US75915K3095

Market Closed - Nasdaq
Other stock markets
 21:00:00 29/04/2024 BST 		5-day change 1st Jan Change
2.52 USD +4.13% Intraday chart for Regulus Therapeutics Inc. +14.55% +96.88%
03-21 Regulus Therapeutics Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
03-21 Regulus Therapeutics Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 CI

Other languages

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Regulus Therapeutics Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
Regulus Therapeutics Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023
Top Midday Gainers
Regulus Therapeutics Reports 'Positive' Data From Second Cohort of Kidney Disease Trial -- Shares Rise
Consumer Prices Tick Higher in February as US Equity Futures Turn Mixed Pre-Bell
Top Premarket Gainers
Regulus Therapeutics Announces Positive Topline Data from the Second Cohort of Patients in Its Phase 1B Multiple-Ascending Dose Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease
Regulus Therapeutics Announces Completion of Enrollment in Third Cohort of Phase 1b Multiple-Ascending Dose Clinical Trial of RGLS8429 for the Treatment of Patients with Autosomal Dominant Polycystic Kidney Disease
Regulus Therapeutics Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
Top Premarket Decliners
Regulus Therapeutics Announces First Patient Dosed in Third Cohort of Phase 1B Multiple Ascending Dose Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease
Regulus Therapeutics Announces Completion of Enrollment in Second Cohort of Phase 1B Multiple-Ascending Dose Clinical Trial of RGSL8429 for the Treatment of Patients with Autosomal Dominant Polycystic Kidney Disease
Regulus Therapeutics Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
Regulus Therapeutics, Inc. Announces First Patient Dosed in Second Cohort of Phase 1b Multiple Ascending Dose Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease
Regulus Therapeutics Inc. Appoints Preston S. Klassen to the Board
Regulus Therapeutics Inc. Appoints Preston S. Klassen to President and Head of Research and Development
Regulus Therapeutics Advances to Cohort 2 of Phase 1B Multiple-Ascending Dose Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease
Regulus Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023
Regulus Therapeutics Expects to Raise About $15 Million in Private Equity Placement; Shares Rise
Regulus Therapeutics Announces Completion of Enrollment in First Cohort of Phase 1b Multiple-Ascending Dose Clinical Trial of RGLS8429 for the Treatment of Patients with Autosomal Dominant Polycystic Kidney Disease
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. RGLS Stock
  4. News Regulus Therapeutics Inc.
  5. Other languages